CLC Number: 

  • R551.2
[1] Tessier-Cloutier B, Clarke AE, Ramsey-Goldman R, et al. Systemic lupus erythematosus and malignancies: a review article[J]. Rheum Dis Clin North Am, 2014, 40(3): 497-506.
[2] Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC cutaneous lymphoma group study of 83 cases[J]. Blood, 2008, 111(2): 838-845.
[3] Apor E, OBrien J, Stephen M, et al. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a metaanalysis of prospective cohort studies[J]. Leuk Res, 2014, 38(9): 1067-1071.
[4] Cerhan JR, Kricker A, Paltiel O, et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph non-Hodgkin lymphoma subtypes project[J]. J Natl Cancer Inst Monogr, 2014, 2014(48): 15-25.doi: 10.1093/jncimonographs/lgu010.
[5] Koff JL, Flowers CR. B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease[J]. Expert Rev Hematol, 2016, 9(6): 553-556.
[6] Lu M, Bernatsky S, Ramsey-Goldman R, et al. Non-lymphoma hematological malignancies in systemic lupus erythematosus[J]. Oncology, 2013, 85(4): 235-240.
[7] Jesus AA, Jacob CM, Silva CA, et al. Common variable immunodeficiency associated with hepatosplenic T-cell lymphoma mimicking juvenile systemic lupus erythematosus[J]. Clin Dev Immunol, 2011, 2011: 428703. doi: 10.1155/2011/428703.
[8] Suzuki A, Shoji N, Aoki N, et al. Systemic lupus erythematosus as the concomitant manifestation of angioimmunoblastic T-cell lymphoma[J]. Mod Rheumatol, 2017, 27(2):360-363.
[9] King JK, Costenbader KH. Characteristics of patients with systemic lupus erythematosus and non-Hodgkins lymphoma[J]. Clin Rheumatol, 2007, 26(9):1491-1494.
[10] Bernatsky S, Ramsey-Goldman R, Rajan R, et al. Non-Hodgkins lymphoma in systemic lupus erythematosus[J]. Ann Rheum Dis, 2005, 64(10):1507-1509.
[11] Hanlon P, Avenell A, Aucott L, et al. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus[J]. Arthritis Res & Ther, 2014, 16(1):R3.
[12] Capone G, Fasano C, Lucchese G, et al. EBV-associated cancer and autoimmunity: searching for therapies[J]. Vaccines, 2015, 3(1):74-89.
[13] Bollard CM, Gottschalk S, Torrano S, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting epstein-barr virus latent membrane proteins[J]. J Clin Onc, 2014, 32(8):798-808.
[14] Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers[J]. Pharmacol & Therap, 2014, 141(2): 125-139.
[15] Miaer-Moore JS, Horton CG, Mathews SA, et al. Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary sjögrens syndrome features in lupus-prone Sle1.yaa mice[J]. Arthritis Rheum, 2014, 66(9): 2521-2531.
[1] . [J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 117-120.
[2] HAN Kangkang, CUI Liwei, PENG Cheng, XUE Yuwen, XIAO Wei. Multiple serous effusion complicated with Warburg effect: a case report of diffuse large B-cell lymphoma and literature review [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 80-87.
[3] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(10): 111-112.
[4] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(2): 109-112.
[5] FANG Xiaosheng, LIU Xin, WANG Xin
.

Expressions of heat shock protein 70 and 90α in nonHodgkin′s lymphoma and its clinical significance

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(04): 83-86.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!